Скачать
Trending in Obesity: Orforglipron Near FDA Decision and more
Автор: LucidQuest
Загружено: 2026-01-21
Просмотров: 2
Описание: AbbVie signals an amylin push from JPM to improve tolerability and durable weight loss. Arrowhead’s interim data suggest ARO-INHBE plus tirzepatide roughly doubles 16-week weight loss and triples 12-week fat reduction in small cohorts. Viking completes enrollment in a VK2735 maintenance study spanning subcutaneous and oral regimens. CorEvitas launches a prospective obesity registry. Lilly targets a potential Q2 2026 orforglipron decision and expands discovery with Nimbus. Alveus raises 160 million dollars for amylin-based programs. Structure projects oral GLP-1 pills reaching 25–50 percent by 2030.
Не удается загрузить Youtube-плеер. Проверьте блокировку Youtube в вашей сети.
Повторяем попытку...
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
